PTC Therapeutics | PTCT - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Cytokinetics USD 104.9M 13.17M 2026-03
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.45B 326M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
TG Therapeutics USD 73.14M 22.42M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xencor USD 82.12M 65.08M 2026-03